La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Adagene Gestione

Gestione criteri di controllo 1/4

Adagene's Il CEO è Peizhi Luo, nominato in Nov2011, ha un mandato di 12.75 anni. possiede direttamente 3.25% delle azioni della società, per un valore di $ 3.60M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.9 anni e 2.8 anni.

Informazioni chiave

Peizhi Luo

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	12.8yrs
Proprietà del CEO	3.3%
Durata media del management	5.9yrs
Durata media del Consiglio di amministrazione	2.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Oct 10

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Aug 30

Micro-cap Adagene surges after hours on $10M share buyback

Jun 29

AMMINISTRATORE DELEGATO

Peizhi Luo (58 yo)

12.8yrs

Mandato

Dr. Peter P. Luo, PhD, also known as Peizhi, is the Founder of Adagene Inc. and serves as its Chief Executive Officer since November 2011 and Director since February 2018. He serves as President of R&D at...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Peter P. Luo	Co- Founder	12.8yrs	Nessun dato	3.25% $ 4.2m
Man Kin Tam	CFO & Director	4.9yrs	Nessun dato	Nessun dato
Jc Xu	Chief Scientific Officer	4yrs	Nessun dato	Nessun dato
Ami Knoefler	Vice President of Investor Relations & Corporate Communications	no data	Nessun dato	Nessun dato
Ling Zhou	Head of Human Resources	4.8yrs	Nessun dato	Nessun dato
Qinghai Zhao	Chief Manufacturing Officer	3.8yrs	Nessun dato	Nessun dato
Yan Li	Senior Vice President of Bioinformatics & Information Technology	12.8yrs	Nessun dato	Nessun dato
Xiaohong She	Senior VP & Head of Clinical Operations	12.8yrs	Nessun dato	0.094% $ 121.1k
Guizhong Liu	Senior Vice President of Early Drug Discovery	8.8yrs	Nessun dato	Nessun dato
Alexander Goergen	VP & Head of Business Development	6.8yrs	Nessun dato	Nessun dato
Jiping Zha	Executive Vice President of Clinical Development	2.8yrs	Nessun dato	Nessun dato
Songmao Zheng	VP and Head of Clinical & Quantitative Pharmacology	no data	Nessun dato	Nessun dato

5.9yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di ADAG è esperto e expertise (durata media dell'incarico 5.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Peter P. Luo	Co- Founder	6.5yrs	Nessun dato	3.25% $ 4.2m
Man Kin Tam	CFO & Director	3.5yrs	Nessun dato	Nessun dato
Li Zhu	Independent Director	less than a year	Nessun dato	Nessun dato
Steven Alan Fischkoff	Member of Scientific & Strategic Advisory Board	3yrs	Nessun dato	Nessun dato
Robert Jay Spiegel	Member Scientific and Strategic Advisory Board	3yrs	Nessun dato	Nessun dato
Mervyn J. Turner	Independent Director	1.3yrs	Nessun dato	Nessun dato
Cuong Viet Do	Independent Director	1.8yrs	Nessun dato	Nessun dato
David R. Gandara	Member Scientific & Strategic Advisory Board	2.6yrs	Nessun dato	Nessun dato
Yumeng Wang	Director	1.3yrs	Nessun dato	Nessun dato
Aurelien Marabelle	Member of Scientific & Strategic Advisory Board	1.4yrs	Nessun dato	Nessun dato
Yiu Leung Cheung	Independent Director	3.5yrs	Nessun dato	Nessun dato
Stanley Frankel	Member Scientific & Strategic Advisory Board	3yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di ADAG non è considerato esperto (durata media del mandato 2.8 anni), il che suggerisce un nuovo consiglio.

Adagene Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Adagene Inc. Announces Board Changes

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

High number of new and inexperienced directors

High number of new and inexperienced directors

Adagene Inc. Announces Board and Management Changes

Recent updates

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.83 loss per share (vs US$1.85 loss in FY 2022)

Adagene Inc. Announces Board Changes

New minor risk - Financial data availability

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody

New major risk - Share price stability

Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium

Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.16

Full year 2022 earnings released: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

Price target decreased by 9.4% to US$12.53

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial

Price target increased to US$13.82

Price target decreased to US$10.78

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

Price target decreased to US$12.71

High number of new and inexperienced directors

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Consensus forecasts updated

Adagene Inc. Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Price target increased to US$27.92

First half 2022 earnings released: US$1.09 loss per share (vs US$1.02 loss in 1H 2021)

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Adagene Inc. (NasdaqGM:ADAG) announces an Equity Buyback for $10 million worth of its shares.

Micro-cap Adagene surges after hours on $10M share buyback

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels

High number of new and inexperienced directors

Adagene Inc. Presents Data Demonstrating First and Best-In-Class Potential for Differentiated Preclinical Antibody Candidates At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$25.69

Adagene Inc. Announces Board and Management Changes

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Adagene Inc. Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1B/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

Director Yu Miao has left the company

Adagene Inc. Announces Clinical Data from its ADG106 NEObodyTM Program

Adagene Inc. Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126 for the Treatment of Various Advanced Solid Tumors

Adagene Inc. has completed an IPO in the amount of $139.726 million.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media